Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis.
about
Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapyMultiple mechanisms mediate resistance to sorafenib in urothelial cancerSorafenib for the treatment of multiple myeloma.Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cellsSorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury.Sorafenib inhibits therapeutic induction of necroptosis in acute leukemia cells.
P2860
Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Two death pathways induced by ...... ted apoptosis and necroptosis.
@en
type
label
Two death pathways induced by ...... ted apoptosis and necroptosis.
@en
prefLabel
Two death pathways induced by ...... ted apoptosis and necroptosis.
@en
P2093
P2860
P50
P1476
Two death pathways induced by ...... ated apoptosis and necroptosis
@en
P2093
A Ramírez-Labrada
L Palomera
N López-Royuela
P2860
P2888
P304
P356
10.1007/S12094-014-1201-Y
P577
2014-07-19T00:00:00Z